About

CervoMed is a clinical stage biotechnology company focused on developing treatments for age-related neurologic disorders.

Until August 2023, CervoMed was known as EIP Pharma Inc.  EIP Pharma Inc is now a wholly-owned subsidiary of CervoMed.

We believe the neurodegenerative process, in the early stages, is primarily comprised of neuroinflammation-induced damage to synapses, which are the interconnections between nerve cells, or neurons. Our lead product candidate, neflamapimod, is currently in clinical development as a treatment for neurodegenerative diseases, such as dementia with Lewy bodies, frontotemporal dementia and recovery after stroke.

We have assembled a highly experienced leadership team to develop and commercialize innovative drug treatments for dementia with Lewy bodies and other central nervous system disorders.